Pulse Biosciences has crossed the halfway mark in a 215-patient pivotal trial, and the timing matters more than the milestone itself. The NANOPULSE-AF study, which launched under FDA Investigational Device Exemption and enrolled its first patients in April, is now past the midpoint with full enrollment targeted for early Q4 2026. That schedule puts Pulse on a path to complete accrual within roughly six months of study initiation, a clip that reflects both pent-up investigator demand and the competitive pressure building in catheter-based atrial fibrillation ablation.
The competitive context here is real and recent. Abbott’s Volt pulsed field ablation system received FDA approval in December 2025 for both paroxysmal and persistent AF, meaning Pulse is running its pivotal trial against a market that now has a cleared PFA option. Pulse’s nPulse platform uses nanosecond pulsed electric field technology, a meaningfully different biophysical mechanism than conventional PFA, and that distinction will carry most of the weight when the company eventually makes its regulatory and commercial case. Whether that distinction translates into differentiated clinical outcomes is precisely what NANOPULSE-AF is designed to answer.
The trial is a single-arm, prospective, multicenter design enrolling patients with recurrent, drug-resistant, symptomatic paroxysmal AF. Single-arm pivotal studies in AF ablation live and die by the strength of their primary endpoints relative to pre-specified performance goals, and the primary safety and effectiveness endpoints here will be the first hard data Pulse has generated in a controlled clinical setting at scale. Crossing the enrollment midpoint means the event clock is now running on the safety follow-up window, and any unexpected adverse event clustering in the back half of enrollment would have compressing consequences on the timeline.
The one number to track from here is the primary effectiveness rate when the dataset locks. Pulse needs that figure to land well above the performance goal threshold to build a differentiation story in a crowded ablation market. A strong result makes the regulatory path straightforward; a marginal one forces a difficult conversation about what nsPEF actually adds over existing cleared platforms.
Source link: https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/plse20260728_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
